

PRESS RELEASE

Hansa Biopharma to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Lund, Sweden, September 4, 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial Analyst at H.C. Wainwright on Monday, September 8th at 2:00 PM EST.

Aguiar-Lucander and Evan Ballantyne, CFO, Hansa Biopharma, will be available for one-on-one meetings on Monday, September 8th and Wednesday, September 10th. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event details: Hansa Biopharma AB Fireside Chat

Date and time: Monday, September 8, 2025, 2:00 PM ET

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

[Webcast Link](#)

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on [LinkedIn](#).

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.